epirubicin has been researched along with Malignant Fibrohistiocytic Tumors in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, X; Lu, WQ; Tong, HX; Wang, ZM; Yang, H; Zhang, SL; Zhang, Y; Zhou, YH; Zhuang, RY | 1 |
| Contreras Ibáñez, JA; Díaz Gómez, L; Navas García, N | 1 |
2 other study(ies) available for epirubicin and Malignant Fibrohistiocytic Tumors
| Article | Year |
|---|---|
Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Apoptosis; Cardiotoxicity; Cell Proliferation; Drug Therapy, Combination; Epirubicin; ErbB Receptors; Female; Heart; Histiocytoma, Malignant Fibrous; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Mice; Mice, Nude; Microvascular Density; Myocardium; Platelet Endothelial Cell Adhesion Molecule-1; Quinolines; Sarcoma; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Mestastatic gastric cancer from malignant fibrous histiocytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dioxoles; Docetaxel; Epirubicin; Fatal Outcome; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Ifosfamide; Lung Neoplasms; Male; Soft Tissue Neoplasms; Spinal Neoplasms; Stomach Neoplasms; Taxoids; Tetrahydroisoquinolines; Thigh; Thoracic Vertebrae; Trabectedin | 2011 |